Hengrui Medicine's oncology drug, HRS-2329, advances; executive adjusts holdings

Jiangsu Hengrui Medicine and its subsidiary, Suzhou CADIYA Biopharmaceuticals, have received NMPA acceptance for the marketing authorization application of their innovative drug, a fixed-dose combination of Camrelizumab for injection and Famitinib malate capsules. This combination is intended for the first-line treatment of recurrent or metastatic cervical cancer. A Phase III clinical trial, which met its primary endpoints in July 2025, supported the application, demonstrating superior event-free survival and overall survival compared to platinum-based chemotherapy.

Separately, Jiangsu Hengrui Medicine also announced the completion of a share reduction plan by director and senior vice president Sun Jieping. Mr. Sun reduced his holdings by 237,040 shares, or 0.004% of the company's total share capital, through centralized bidding between July 9 and September 25, 2025. The shares were sold at prices ranging from RMB 57.01 to RMB 73.95, totaling RMB 15,633,183.67.

Additionally, the company received clinical trial approval for HRS-2329 tablets, an innovative anti-tumor drug, for patients with advanced solid tumors carrying RAS mutations or amplification. The company has invested approximately RMB 60.15m in this project. Separately, 10,000 A-shares were repurchased on September 30, 2025, at RMB 69.45 per share, totaling RMB 694,500, to be held in treasury for an employee stock ownership plan.